- Home
- MCHX vs AVTE Comparison
MCHX vs AVTE Comparison
Compare MCHX & AVTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCHX
- AVTE
- Stock Information
- Founded
- MCHX 2003
- AVTE 2018
- Country
- MCHX United States
- AVTE United States
- Employees
- MCHX N/A
- AVTE N/A
- Industry
- MCHX Business Services
- AVTE Biotechnology: Pharmaceutical Preparations
- Sector
- MCHX Consumer Discretionary
- AVTE Health Care
- Exchange
- MCHX Nasdaq
- AVTE Nasdaq
- Market Cap
- MCHX 84.3M
- AVTE 68.7M
- IPO Year
- MCHX 2004
- AVTE 2021
- Fundamental
- Price
- MCHX $1.97
- AVTE $2.37
- Analyst Decision
- MCHX
- AVTE Hold
- Analyst Count
- MCHX 0
- AVTE 7
- Target Price
- MCHX N/A
- AVTE $11.75
- AVG Volume (30 Days)
- MCHX 43.5K
- AVTE 140.8K
- Earning Date
- MCHX 03-13-2025
- AVTE 03-24-2025
- Dividend Yield
- MCHX N/A
- AVTE N/A
- EPS Growth
- MCHX N/A
- AVTE N/A
- EPS
- MCHX N/A
- AVTE N/A
- Revenue
- MCHX $48,594,000.00
- AVTE N/A
- Revenue This Year
- MCHX N/A
- AVTE N/A
- Revenue Next Year
- MCHX $4.63
- AVTE N/A
- P/E Ratio
- MCHX N/A
- AVTE N/A
- Revenue Growth
- MCHX N/A
- AVTE N/A
- 52 Week Low
- MCHX $1.11
- AVTE $1.25
- 52 Week High
- MCHX $2.40
- AVTE $32.42
- Technical
- Relative Strength Index (RSI)
- MCHX 49.04
- AVTE 37.24
- Support Level
- MCHX $1.92
- AVTE $2.35
- Resistance Level
- MCHX $2.05
- AVTE $2.49
- Average True Range (ATR)
- MCHX 0.10
- AVTE 0.10
- MACD
- MCHX -0.00
- AVTE -0.01
- Stochastic Oscillator
- MCHX 33.33
- AVTE 11.43
About MCHX Marchex Inc. Class B
Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.
About AVTE Aerovate Therapeutics Inc.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.